LyondellBasell Industries N.V. (LYB)

FairStock Score: 47/100 — MIXED

Key Financials

Strengths

• Free cash flow of $447M provides some financial flexibility despite current losses
• Global diversification across Americas, Europe, and Asia reduces regional concentration risk
• Low beta of 0.67 suggests relative stability compared to broader market
• Market capitalization of $21.5B provides liquidity and scale advantages
• Reasonable valuation entry point if cyclical trough is truly behind us

Concerns

• Negative profitability in Q4 2025 with -2% net margin signals severe operational distress
• Astronomical EV/EBITDA of 87.25x is unsustainable and suggests market pricing in recovery risk
• Negative ROE of -6.95% and Altman Z-Score of 1.19 indicate financial distress territory
• High leverage at 1.44x debt-to-equity ratio is precarious for a cyclical business with declining earnings

AI Analysis

LyondellBasell presents a deeply troubled picture that would give me considerable pause. This is a cyclical chemical manufacturer caught in a severe downturn—evidenced by a negative $142 million net income in Q4 2025 and a -2% profit margin. The company trades at an astronomical 87.25x EV/EBITDA, which is indefensible regardless of the cycle. More troubling: negative ROE of -6.95%, a Piotroski F-Score of just 4/9 suggesting deteriorating financial health, and an Altman Z-Score of 1.19 placing it in the distress zone. The debt-to-equity ratio of 1.44 is uncomfortably high for a company with eroding profitability. While the 4.9% FCF yield appears attractive on surface, I'm skeptical—free cash flow generation in a down cycle doesn't reflect normalized earnings power. The company's competitive moat in commodity chemicals is paper-thin; it competes on cost and scale in a fiercely competitive, cyclical industry. I see no durable competitive advantages worth paying up for. The positive: a $21.5B market cap with global reach, reasonable FCF generation at $447M, and a low beta of 0.67 suggesting relative stability. However, without visible earnings, improving fundamentals, or a clear catalyst, I cannot justify a position. The risk-reward tilts decidedly unfavorable.

Bull Case

If chemical demand recovers with economic stimulus or normalization post-recession, LyondellBasell's global scale and integrated operations position it to benefit significantly. The current valuation trough could prove temporary if management executes cost reductions and the cycle turns—FCF generation could re-accelerate rapidly.

Bear Case

Continued economic weakness, oversupply in commodity chemicals, or structural decline in demand could push the company toward covenant violations or distressed debt restructuring. The negative earnings trajectory suggests management cannot maintain current dividend or capex levels, risking shareholder capital destruction.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer